Permanent Link:
http://vlex.com/vid/endpoint-adefovir-dipivoxil-infection-52853395
Id. vLex: VLEX-52853395
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
REPEATING/Gilead Achieves Primary Endpoint in Phase III Study of Adefovir Dipivoxil for Chronic Hepatitis B Virus Infection.
Business Editors/Health & Medical Writers
REPEATING....Due to Garble on Line FOSTER CITY, Calif.--(BW HealthWire)--June 22, 2001 Improvement in Liver Histology Demonstrated in 53 Percent of Patients Gilead Sciences, Inc. (Nasdaq:GILD) today announced interim 48-week data from a Phase III clinical trial (Study 437) evaluating the safety and efficacy of adefovir dipivoxil once daily as monotherapy compared to placebo in patients with chronic hepatitis B virus (HBV) infection. Results from this intent-to-treat analysis meet the study's prima...Try vLex for FREE for 3 days
Access legal information from United States including:
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here